Notably, for patients with mKRAS mutations and squamous cell carcinoma, targeted treatment regimens and the addition of cetuximab, respectively, showed significant enhancements in survival rates, regardless of the KRAS mutation status [69,74]. This evidence concerns the gene KRAS and squamous cell carcinoma.